230 related articles for article (PubMed ID: 16469521)
1. Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis.
Salotra P; Duncan RC; Singh R; Subba Raju BV; Sreenivas G; Nakhasi HL
Microbes Infect; 2006 Mar; 8(3):637-44. PubMed ID: 16469521
[TBL] [Abstract][Full Text] [Related]
2. Genetic fingerprinting and identification of differentially expressed genes in isolates of Leishmania donovani from Indian patients of post-kala-azar dermal leishmaniasis.
Subba Raju BV; Singh R; Sreenivas G; Singh S; Salotra P
Parasitology; 2008 Jan; 135(Pt 1):23-32. PubMed ID: 17761024
[TBL] [Abstract][Full Text] [Related]
3. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
5. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
[TBL] [Abstract][Full Text] [Related]
6. A clinical isolate of Leishmania donovani with ITS1 sequence polymorphism as a cause of para-kala-azar dermal leishmaniasis in an Ethiopian human immunodeficiency virus-positive patient on highly active antiretroviral therapy.
Gelanew T; Amogne W; Abebe T; Kuhls K; Hailu A; Schönian G
Br J Dermatol; 2010 Oct; 163(4):870-4. PubMed ID: 20331449
[TBL] [Abstract][Full Text] [Related]
7. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K
Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis.
Sharma P; Gurumurthy S; Duncan R; Nakhasi HL; Salotra P
Parasitol Int; 2010 Jun; 59(2):262-4. PubMed ID: 19963076
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.
Dey A; Singh S
Infect Genet Evol; 2007 Mar; 7(2):219-22. PubMed ID: 17027344
[TBL] [Abstract][Full Text] [Related]
10. Implications of co-infection of Leptomonas in visceral leishmaniasis in India.
Selvapandiyan A; Ahuja K; Puri N; Krishnan A
Parasitology; 2015 Dec; 142(14):1657-62. PubMed ID: 26492813
[TBL] [Abstract][Full Text] [Related]
11. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
Subba Raju BV; Gurumurthy S; Kuhls K; Bhandari V; Schnonian G; Salotra P
Parasitol Res; 2012 Oct; 111(4):1559-68. PubMed ID: 22752721
[TBL] [Abstract][Full Text] [Related]
12. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
13. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal.
Das ML; Deb M; Karki BM; Sarif M; Khanal B; Bhattacharya SK; Agrawal S; Koirala S
Southeast Asian J Trop Med Public Health; 2007 Jul; 38(4):619-25. PubMed ID: 17882997
[TBL] [Abstract][Full Text] [Related]
14. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S; Das NK; Barbhuiya JN; Chatterjee M
Int J Dermatol; 2010 Aug; 49(8):921-31. PubMed ID: 21128917
[TBL] [Abstract][Full Text] [Related]
16. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis.
Salotra P; Sreenivas G; Pogue GP; Lee N; Nakhasi HL; Ramesh V; Negi NS
J Clin Microbiol; 2001 Mar; 39(3):849-54. PubMed ID: 11230394
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
18. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
19. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
20. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
